Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders
OpenAlex – December 18, 2025
Source: OpenAlex
Summary
Imagine a therapy where a single psychedelic session could unlock rigid personality patterns. Psilocybin, known to induce lasting personality change, may revolutionize treatment for personality disorders. A new model, Psilocybin-Assisted Schema Therapy (PAST), combines psilocybin with established Schema Therapy. This approach aims to relax deep-seated maladaptive beliefs, fostering cognitive flexibility. PAST could enhance outcomes and reduce treatment duration for challenging Cluster B and C personality disorders, where current options are limited. This framework outlines future studies on its potential.
Abstract
Personality disorders (PDs) are characterized by rigid and maladaptive patterns of self- and interpersonal functioning, leading to high clinical burden and limited treatment outcomes. Schema Therapy (ST), an integrative psychotherapy rooted in cognitive-behavioral principles, conceptualizes PDs in terms of Early Maladaptive Schemas (EMS)—pervasive cognitive–affective structures formed through unmet emotional needs—and schema modes, dynamic states organizing emotion, belief, and behavior. Evidence indicates moderate efficacy of ST, mainly for borderline personality disorder, with limited research on other Cluster B and C PDs. Emerging evidence suggests that psilocybin, a serotonergic psychedelic, can induce enduring personality change, supporting its potential use in treating PDs. Within a predictive coding framework, the REBUS (“Relaxed Beliefs Under Psychedelics”) and REBAS (“Revised Beliefs After Psychedelics”) models propose that psilocybin relaxes high-level priors, facilitating cognitive flexibility and revision of maladaptive self-beliefs. Conceptual parallels between EMS and high-level priors suggest that psychedelic-induced relaxation of entrenched beliefs may enhance responsiveness to ST’s experiential and cognitive interventions. Psilocybin-Assisted Schema Therapy (PAST) is proposed as a model in which psilocybin sessions are followed by integration combining psychedelic-induced cognitive flexibility with ST techniques, aimed at strengthening adaptive modes and reducing dysfunctional EMS and dysfunctional modes. PAST could be relevant in the future for enhancing outcomes and potentially reducing treatment duration in Cluster B and C PDs, pending empirical validation. Although current literature is insufficient to recommend psilocybin-assisted interventions for PDs, this theoretical article bridges computational neuroscience and clinical psychotherapy, outlining a framework for future studies on PAST feasibility, safety, and efficacy.